持续静脉滴注氟尿嘧啶联合顺铂治疗晚期头颈部癌  

Analysis of chemotherapy with 5-FU by continous intravenous infusion and cisplatin in head and neck advanced cancer

作　　者：罗志国[1] 常建华[1] 于慧[1] 吕方芳[1] 吴向华[1] 郭晔[1] 李进[1] 

机构地区：[1]复旦大学附属肿瘤医院肿瘤内科,复旦大学上海医学院肿瘤学系,上海200032

出　　处：《中国癌症杂志》2007年第9期716-718,共3页China Oncology

摘　　要：背景与目的:顺铂与氟尿嘧啶是治疗晚期头颈部肿瘤疗效确切的药物,但有一定的毒性反应。本研究观察持续静脉滴注氟尿嘧啶联合顺铂治疗晚期头颈部癌的疗效及安全性。方法:22例晚期头颈部癌患者给予氟尿嘧啶750mg/(m2.d)持续静脉滴注5d(120h),顺铂25mg/(m2.d),d1～3。21d为一个周期,2个周期后评价疗效。结果:CR1例(4.5%),PR8例(36.4%),近期客观有效率为40.9%(9/22)。中位TTP7.4个月,1年生存率为72.7%。初治与复治有效率分别为75.0%(6/8),21.4%(3/14),统计学差异有显著性(χ2=6.04,P<0.05)。主要毒副反应为骨髓抑制、胃肠道反应和粘膜炎。结论:持续静脉滴注氟尿嘧啶联合顺铂治疗晚期头颈部癌具有较好的疗效,安全性好。Background and purpose：Cisplatin and 5-fluorouracil （5-FU） have demonstrated significant activity in patients with advanced head and neck cancer despite relevant toxicity. We evaluated the efficacy and toxicity of combination chemotherapy using continuous intravenous infusion 5-FU plus cisplatin for locally advanced, recurrent, or metastatic head and neck cancer patients. Methods：twenty-two patients with locally advanced, recurrent, or metastatic head and neck cancer were treated by cisplatin 25 mg/（m2·d） day 1-3 and fluorouracil 750 mg/（m2·d） 120 hours by continuous intravenous infusion day 1 through 5 every 21 days as one cycle.Results：Of 22 assessable patients, 1 （4.5%）showed completed response and 8 partial response with an overall response rate of 40.9%（9/22）. Median time to progression was 7.7 months, and 1-year survival was 72.2%. The toxicity mainly included grade 1/2 myleosuppression, reaction of stomach intestinal, mucositis. Response rate of initial treatment and retreatment were 75.0%（6/8）,21.4%（3/14）, respectively （χ2=6.04,P〈0.05）.Conclusions：chemotherapy with 5-FU by continous intravenous infusion and cisplatin is safe and effective for patients with locally advanced, recurrent, or metastatic head and neck cancer.

关 键 词：头颈部肿瘤 氟尿嘧啶 顺铂 晚期 化学治疗 

分 类 号：R730.53[医药卫生—肿瘤]